Updated on 24 May 2016
Excelra, headquartered in Hyderabad, India, has announced its collaboration with H M Pharma Consultancy (HMPC), a life science consulting enterprise based in Austria, to jointly provide Drug Repurposing services to pharma and biotech companies across Europe.
Drug Repurposing at Excelra is driven by its proprietary platform called GRIP-Global Repurposing Integrated Platform. The platform uses unique algorithm driven techniques that allow you to expedite drug centric, disease centric and target centric repurposing of marketed and failed/shelved compounds. Excelra partners with clients to offer end-to-end drug repurposing collaborative research services starting form In-silico hypothesis generation to IND enabling studies.
Excelra Knowledge Solutions (formerly GVK Informatics) is an Informatics Solutions company that leverages its scientific knowledge base, technology and relevant domain expertise to provide intelligent data and analytics solutions to customers globally.
H M Pharma Consultancy addresses clients' repurposing needs based on its knowledge of biological pathways, deep context mining of the scientific literature, patent documents and other text-based sources. Through this collaboration, Excelra and HMPC aim at utilizing joint expertise towards co-developing innovative applications of known drugs and compounds to new indications for clients in Europe.
Dr Nandu Gattu, Vice President, Drug Repurposing, Excelra, said, "Both parties will work together to support areas of drug repurposing. HMPC provides us with complementing skill-sets and know-how on their knowledge driven expertise in the area of drug re-profiling. This collaboration is an example of our assurance towards providing accelerated innovation to our potential partners in the European life science community."
Dr Hermann Mucke, HMPC's Proprietor and Executive Officer, said, "Drug repurposing is an effort that requires multidisciplinary approaches. The collaboration with Excelra enables us to identify potential opportunities that would not have been evident otherwise. We now look forward to being able to serve our customers even better, with broader perspectives on drug repurposing and facilitate Excelra's business solutions in Europe."